| Code | CSB-RA011587MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ustekinumab-Aauz, targeting IL12B (interleukin-12 subunit beta), also known as the p40 subunit. IL12B is a shared component of both interleukin-12 (IL-12) and interleukin-23 (IL-23), two critical cytokines that regulate T-helper cell differentiation and immune responses. By binding to the p40 subunit, this antibody inhibits both IL-12 and IL-23 signaling pathways, which play central roles in inflammatory and autoimmune processes. Dysregulation of IL12B-mediated signaling is implicated in various immune-mediated conditions including psoriasis, psoriatic arthritis, Crohn's disease, and other chronic inflammatory disorders.
Ustekinumab-Aauz serves as the reference therapeutic antibody for this biosimilar product. This research-grade antibody provides investigators with a valuable tool for studying IL-12/IL-23 pathway biology, investigating mechanisms of immune dysregulation, evaluating cytokine-mediated inflammation, and exploring therapeutic interventions in preclinical models of autoimmune and inflammatory diseases. It supports experimental research into T-cell biology and cytokine network interactions.
There are currently no reviews for this product.